American Health Intel Rules. Money. Medicine. Decoded daily.
Subscribe
The Service Line · Saturday, November 21, 2026

The Service Line

Rules. Money. Medicine. Decoded daily.
6 stories · 5 min read
Reading as

Pharmacies and the Medicare drug plans that contract with them have until Monday to tell the government what a “reasonable” network contract looks like, and the agency is asking for actual contract language. The Centers for Medicare & Medicaid Services (CMS) request for information, CMS-4217-NC in the Federal Register, was published September 24 with a 60-day comment window, so it closes November 23. Section 6223 of the Consolidated Appropriations Act, 2026 requires Part D plan sponsors to admit any pharmacy that accepts their standard terms, and from January 1, 2029 those terms must be “reasonable and relevant.” The notice says CMS “has not established additional requirements” for what that means, and the Secretary must set standards by the first Monday in April 2028. CMS asks about reimbursement and dispensing fees, how often plans update maximum allowable cost (MAC) pricing lists, audits that recoup payment over minor errors, and limits on what a network pharmacy may dispense. It invites de-identified contract language and data split by pharmacy type, geography and drug category, and asks how vertical integration should factor in. Who it hits: independent and rural pharmacy owners, the group purchasing and contracting organizations that negotiate for them, and every plan and pharmacy benefit manager (PBM) that writes network terms. This is the first time the definition is being built from the record, and what gets filed this weekend becomes that record. This answers our recurring question on what state and federal PBM rules mean for your contract audit rights. Confidence: High on the terms and the November 23 close, which follow from the notice’s 60-day window and match Drug Topics; Low on where CMS lands, since this is an information request only.

Reimbursement: CMS finalized the 2029-and-later rulebook for Medicare drug price negotiation, and left Part B payment mechanics out

CMS issued the final rule governing Medicare drug price negotiation for 2029 onward on November 5, 695 pages, with a temporary price floor for certain small biotech drugs. Per Covington’s summary, the rule was scheduled for Federal Register publication November 9, and CMS’s earlier guidance keeps governing products selected for 2026 through 2028 until January 1, 2029. Drug Channels, reading the CMS fact sheet, reports the rule does not set how negotiated prices are paid for Part B drugs, and adds a provision letting CMS group products that share an active ingredient and application holder. So-what: practices that buy and bill physician-administered drugs still have no written payment mechanism for negotiated Part B prices, so contract and cash-flow planning for those drugs stays open-ended. We did not open the rule text itself this run. Confidence: Medium, resting on the law-firm summary and trade reading of the CMS fact sheet. Also see Drug Channels’ November roundup.

Enforcement: A Michigan pharmacy owner got 82 months for billing for drugs no doctor ordered and no patient received

Ali Naserdean of Dearborn Heights, who worked as a pharmacy technician and owned one of three metro Detroit pharmacies, was sentenced this week to 82 months in federal prison in a $5.6 million health care fraud and oxycodone case. Per Becker’s ASC, he was ordered to pay $3,654,895.65 to the Department of Health and Human Services and $21,428.93 to Blue Cross Blue Shield of Michigan. The Justice Department plea announcement describes claims for prescriptions not ordered by a doctor and not dispensed, from 2019 through 2022, plus sales of oxycodone to drug traffickers for cash. So-what: this is the billed-but-never-dispensed pattern, and the control that catches it is a monthly match of paid claims against dispensing and pickup records, with reversals logged for anything returned to stock. We could not retrieve the Justice Department’s sentencing release, and sources differ on whether the date was November 17 or 18. Confidence: Medium on the sentence and figures (secondary report, consistent with the plea release); High on the scheme as charged. Status checks: we found no final FTC order against Optum Rx and no Eighth Circuit ruling yet on Arkansas Act 624.

Who’s Buying: A mid-size PBM consolidates again, and a wholesaler goes deeper into infusion

MedImpact agreed to acquire the PBM business of VytlOne and its rebate-aggregator affiliate Gateway Health Partners, with VytlOne keeping its 340B, specialty pharmacy and fulfillment assets. Drug Channels reported it on November 17 without terms, and frames it as part of the shakeout among smaller PBMs. The related thread is older but still moving: McKesson and the private equity firm Clayton, Dubilier & Rice agreed October 6 to buy Option Care Health, a home infusion pharmacy operator, for about $5.8 billion including debt at $32.05 a share, with the equity firm holding about 51% and McKesson investing about $1.4 billion for about 49%, per the Option Care press release filed with the SEC. Close is expected in the first half of 2027. So-what: the independent PBM tier is getting bigger by purchase, and wholesalers keep buying positions where provider-administered drugs are dispensed, which is where biosimilar margin is moving. Confidence: Medium on MedImpact (one trade report, no terms); High on Option Care terms; Low on any strategic read.

Clinical Policy: One flooded injectables plant in India explains why three chemotherapy drugs stay scarce into 2028

A July 23 monsoon flood closed the Pfizer and Zydus joint-venture oncology injectables plant in Ahmedabad, and Pfizer’s best case for new supply is mid-to-late 2028. CancerNetwork (November 2) reports the plant, rated at 7 million vials a year, is still closed, and that the American Society of Health-System Pharmacists (ASHP) database lists flood-related delays behind shortages of cytarabine, irinotecan and bleomycin injections. So-what: health-system and oncology pharmacies should assume these three stay on allocation or substitution protocols through 2027, and price the staff time to manage them. This comes from our frontier scan of the pharmacy supply chain. We could not resolve the ASHP and Fierce Pharma links the article cites. Confidence: Medium, single trade source for the plant facts.

The Operator Metric: 225

ASHP counts 225 active U.S. drug shortages in the third quarter of 2026, essentially flat on 227 in the second quarter, but 87 new shortages through September already nearly equal all of 2025’s 89. The ASHP shortage statistics page is the primary source; its cached page still showed the second-quarter figure when we checked, so the third-quarter numbers rest on CancerNetwork’s report of the ASHP release. The all-time high is 323, in early 2024. A flat total hides a faster inflow, so track new shortages touching your own formulary each month, not the national count. Confidence: Medium on the third-quarter figures; High on the 2024 high.


Get tomorrow's edition in your inbox.

Free. One email a day at 6pm your time, or one summary every Friday. Switch or stop anytime.

Where these stories are tracked
Get the next issue Free, daily